Updated analysis and forecasts based on Q3 2017 company-reported sales.
PharmaVitae explores Bayer's prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016-26.
- Overview - Bayer's prescription drug sales will experience modest growth up to 2026.
- Out to 2022 - Bayer's prescription drug sales will grow rapidly out to 2022, reaching total sales of $22.8bn.
- Out to 2026 - Following major patent expiries in 2023, sales will marginally decline to $22.5bn in 2026.
- Pipeline - Diabetic nephropathy treatment finerenone set for approval in 2020.
- Events - Completion of Monsanto acquisition, and updates to Xarelto's label.
- Bayer's prescription drug sales will experience modest growth up to 2026.
- Genitourinary remains a key therapy area, despite little R&D involvement. Sales of contraceptive franchises Yaz and Mirena will drive sales in the segment.
- Internal cardiovascular research will provide long-term sales growth.
- Bayer's in-licensing strategy will continue to have moderate success.
- Added vilaprisan
- ODM-201 changed to darolutamide
- Copanlisib changed to Aliqopa.
- Explore and visualize revenue dynamics in Bayer's portfolio out to 2026 using 10-year in-house sales forecasts segmented by the following sections.
- How is Bayer strategically poised out to 2026?
- What are Bayer's key strengths, weaknesses, opportunities, and threats?
- What are Bayer's key catalysts during the current year?
Facts and figures:
- What is Bayer's forecasted sales performance out to 2026?
- What is the revenue trajectory of Bayer's current top 10 products out to 2026?
- Which therapy areas will experience the largest growth and decline?
- What are the portfolio weightings of Bayer based on the lifecycle of its products?
Key therapy areas:
- Why will specific therapy areas experience the largest growth and decline?
- What are the detailed competitive dynamics at play in Bayer's important therapeutic markets?
- How is Bayer adapting strategically to internal and external headwinds?